A collection of research progress at the 2022 EBMT Annual Meeting

The European Society of Blood and Marrow Transplantation (EBMT) annual meeting is one of the most influential international conferences in the field of blood disease treatment.
The 48th EBMT annual meeting in 2022 will be held in the form of an online virtual meeting from March 19 to 23.
The meeting Covers major advances related to hematopoietic stem cell transplantation and cell therapy research
.

[Yimaitong Hematology Department] carried out an inventory, and took everyone to review the research progress of the 2022 EBMT Annual Meeting
.

Click on "Related Article Titles" to read related articles
.

01 Research progress related to CAR-T therapy P.
Derigs et al.
, Heidelberg University Hospital, Germany, initiated a phase 1/2 clinical trial to evaluate the application of dose-escalating CD19 CAR after fludarabine/cyclophosphamide lymphocyte depletion chemotherapy -Efficacy and safety of T in patients with advanced B-cell malignancies
.

For details, please see: 2022 EBMT | Third-generation CD19-targeted CAR-T is used in patients with relapsed/refractory chronic lymphocytic leukemia.
The team of Prof.
Jiang Erlie from the Hospital of Hematology, Chinese Academy of Medical Sciences applied a case of AML patients who relapsed after allo-HSCT.
The efficacy and safety of universal anti-CD123 chimeric antigen receptor-γδT (CAR-γδT) cells combined with donor lymphocyte infusion (DLI) were evaluated
.

For details, please refer to: 2022 EBMT Voice of China | Universal anti-CD123 CAR-γδ T cells combined with donor lymphocyte infusion in the treatment of 02 hematopoietic stem cell transplantation in patients with relapsed AML after allo-HSCT.
World study to investigate the effect of allogeneic hematopoietic stem cell transplantation (allo-HCT) on overall survival (OS), disease-free survival (DFS) and non-relapse mortality in adult patients with acute lymphoblastic leukemia (ALL)
.

For details, please see: 2022 EBMT Review | Professor Jiang Erlie: Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Progress The prognosis, efficacy, and tolerability of systemic lymphoma (PCNSL) were studied
.

For details, please refer to: 2022 EBMT Review | Prof.
Huang Wenrong: Research Progress of Autologous Hematopoietic Stem Cell Transplantation for Consolidation Treatment of PCNSL Researchers from Russia and the First Affiliated Hospital of Sun Yat-Sen University respectively conducted two studies to explore the efficacy of tandem ASCT and tandem ASCT Comparison of efficacy with allogeneic hematopoietic stem cell transplantation (allo-SCT)
.

Read more: 2022 EBMT | Tandem ASCT Improves Outcomes in Multiple Myeloma Patients Two studies investigated the outcomes of ASCT in patients with multiple myeloma (MM)
.

For details, please see: 2022 EBMT | ASCT still plays an important role in multiple myeloma patients in the era of new drugs Italian and Turkish researchers conducted studies to explore the use of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia (AML) ( allo-HSCT)
.

For details, please see: 2022 EBMT | What is the prognosis of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia? Peripheral T-cell lymphomas (PTCLs) are a rare group of aggressive non-Hodgkin lymphomas that arise from mature T lymphocytes and in most cases are characterized by a refractory or relapsed course after standard therapy
.

We conducted a retrospective multicenter analysis of the treatment of peripheral T-cell lymphoma (PTCL) with a focus on hematopoietic stem cell transplantation (HSCT)
.

For details, please see: 2022 EBMT | What is the role of hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphoma? Spanish and Algerian scholars conducted separate studies to explore the prognosis of primary myelofibrosis (PMF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT)
.

For more information, see: 2022 EBMT | What is the prognosis for patients with primary myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation? In the era of novel drugs, the role of hematopoietic stem cell transplantation (HSCT) in mantle cell lymphoma (MCL) remains uncertain
.

Therefore, Greek investigators compared treatment strategies and survival outcomes in patients with current-stage and early-stage MCL
.

For more details, see: 2022 EBMT | The role of hematopoietic stem cell transplantation in mantle cell lymphoma: results of a single-center exploratory study Khouri et al.
High efficacy and low toxicity have been shown in leukemia (CLL) and non-Hodgkin lymphoma, but have not been evaluated in Hodgkin lymphoma patients
.

A study by A.
Beynarovich et al.
, Russia, was conducted to evaluate the effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on relapsed/refractory classical Hodgkin lymphoma (R/R HL) under a new treatment regimen.
) in patients
.

For details, please see: 2022 EBMT | New Drug Era, Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Efficacy and cost-effectiveness of salvage autologous hematopoietic stem cell transplantation (sASCT) in post-relapsed multiple myeloma (MM) patients
.

For details, please see: 2022 EBMT Voice of China | Salvage ASCT is a Cost-Effective Treatment Option for Multiple Myeloma Patients Relapsed After ASCT Patients with severe aplastic anemia (SAA) who received haploid stem cell transplantation (haplo-SCT) as salvage therapy were included
.

Long-term outcomes were assessed, focusing primarily on patient survival and quality of life (QoL)
.

For details, please see: 2022 EBMT Voice of China | Long-term follow-up results of haploid transplantation in patients with severe aplastic anemia: a multicenter prospective study Reducing the relapse rate after allo-HSCT and improving long-term survival in the leukemia (B-ALL) population deserves further attention
.

A related study was conducted by the First Affiliated Hospital of Zhejiang University School of Medicine
.

For details, please refer to: 2022 EBMT Voice of China | What is the effect of haplo-HSCT in R/R B-ALL after CAR-T treatment? Researchers from the Hospital of Hematology, Chinese Academy of Medical Sciences conducted a study to establish a well-established QoL assessment system and explore the differences in long-term QoL between MSD HSCT and HID HSCT
.

For details, please see: 2022 EBMT Voice of China | Compared with sibling congenital transplantation, haploidentical transplantation achieves better quality of life without compromising survival 03 Research progress on conditioning regimens before transplantation The optimal consolidation regimen for (T-LBL) has not been established
.

The optimization of graft-versus-host disease (GVHD) prevention strategies and the prevention of complications such as infection has resulted in a significant decrease in non-relapse mortality (NRM) over the past few decades
.

There is a clinical need to explore the optimal conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) to reduce the risk of relapse and improve survival in adult T-LBL patients
.

For details, see: 2022 EBMT Voice of China | TBI conditioning regimen improves survival in patients with T-LBL treated with allo-HSCT A study from the Hospital of Hematology, Chinese Academy of Medical Sciences evaluated a novel conditioning regimen (containing decitabine [Dec ] + busulfan [Bu] + cyclophosphamide [Cy] + fludarabine [Flu]/cladribine [CdA] + cytarabine [Ara-c]) for allogeneic hematopoietic stem cell transplantation (allo -HSCT) efficacy in CMML patients
.

For details, please refer to: 2022 EBMT Voice of China | An improved conditioning regimen can provide better outcomes for adult CMML patients undergoing allogeneic hematopoietic stem cell transplantation For evaluation of porcine antilymphocyte globulin (P-ALG) and rabbit antithymocyte globulin The efficacy and safety of (R-ATG) in the conditioning regimen of patients with acquired aplastic anemia receiving HLA haploidentical hematopoietic stem cell transplantation (halpo-HSCT), the team of Professor Sizhou Feng from the Hospital of Hematology, Chinese Academy of Medical Sciences conducted a related study.
research
.

For details, please see: 2022 EBMT Voice of China | P-ALG is expected to replace R-ATG in acquired aplastic anemia patients treated with halpo-HSCT Effects of combined busulfan (Bu)/cyclophosphamide (Cy) preconditioning on auto-HSCT in AML patients
.

For details, please see: 2022 EBMT | Cladribine combined with busulfan/cyclophosphamide conditioning regimen for autologous hematopoietic stem cell transplantation in acute myeloid leukemia for the efficacy of allogeneic hematopoietic stem cell transplantation, and it has been promoted and applied worldwide
.

The number of clinical studies of chimeric antigen receptor T-cell (CAR-T) therapy exceeds that of the United States
.

Compared with 2021 (2 oral presentations and 10 poster presentations), this year Chinese experts have 7 oral presentations and 60 poster presentations shortlisted for the EBMT annual meeting
.

For details, please refer to: 2022 EBMT | Chinese researchers make a strong voice in the field of cell therapy and transplantation! 67 reports were selected, a year-on-year increase of 4.
6 times! The National Clinical Research Center for Hematological Diseases and the Institute of Hematology of Peking University selected 1 invited report, 3 oral reports (Oral) and 5 posters (Poster) at the annual meeting this year.
Hematopoietic reconstitution, cell therapy, graft-versus-host disease (GVHD), infection and translational medicine are all highlighted
.

For details, please refer to: 2022 EBMT | National Blood Clinical Research Center team selected multiple achievements of the 48th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting A study was conducted at the First Affiliated Hospital of Sun Yat-Sen University to evaluate cyclophosphamide Efficacy and safety of two different infusion times of (Cy) + colony stimulating factor (G-CSF) in peripheral blood stem cell mobilization in newly diagnosed multiple myeloma (NDMM) patients
.

For more details, please see: 2022 EBMT Voice of China | Prolonged cyclophosphamide infusion time as a stem cell mobilization regimen for NDMM patients is more effective: a retrospective single-center study of ruxolitinib, a Janus kinase inhibitor, has been approved by the United States FDA-approved for the treatment of hormone-refractory acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) in adults and children (≥12 years of age) who have failed first- or second-line systemic therapy
.

A number of research progresses on ruxolitinib in the treatment of post-transplant GVHD were included in EBMT
.

For details, please see: 2022 EBMT | Research Progress of Ruxolitinib in the Treatment of Graft Versus Host Disease Cytomegalovirus (CMV) infection is a common complication after hematopoietic stem cell transplantation (HSCT), which seriously threatens the survival and prognosis of patients.
For the "Troll of Transplant", Yimaitong took stock of CMV-related issues and research at this conference
.

For details, please refer to: EBMT 2022 | "Move" together, enjoy the CMV academic feast together! Investigators have performed 38 extracorporeal photodissection (ECP) treatments, 22 (58%) with peripheral venous access and 16 (42%) with only central venous access
.

No serious adverse events have been identified to date
.

The investigators treated three patients with chronic GVHD and attempted to treat one patient with non-Hodgkin's lymphoma-peripheral T-cell lymphoma
.

For more details, please see: 2022 EBMT | Extracorporeal Photoabsorptive Replacement Therapy - A Case for Chronic GVHD Treatment Based on New Experience A related study by C.
Anthias et al.
Safety and efficacy in systemic malignancies
.

Details at: 2022 EBMT | Cord Blood Transplantation for Hematological Malignancies Has Favorable Engraftment Rates and Low TRM Rates Efficacy has been demonstrated in preclinical models (GVHD)
.

Chinese scholars investigated the safety and efficacy of SHR0302 combined with prednisone as first-line treatment for newly diagnosed chronic graft-versus-host disease (cGVHD) after allo-HSCT
.

For details, please refer to: 2022 EBMT Voice of China | Phase I results of JAK1 inhibitor SHR0302 + prednisone for first-line treatment of cGVHD after allo-HSCT Typesetting: Wenting Execution: XY poke "read the original text", let's make progress together